$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Abdominal aortic aneurysm (AAA) affects >35 million people worldwide, and 4–8% of men aged 65-801,2. Rupture, the most devastating complication of AAA, typically occurs when the mechanical wall stress of the aneurysm exceeds the strength of the aortic tissue, leading to massive hemorrhage and an overall mortality rate of 80−90%3,4. Current management is aimed at prevention, with ultrasound screening of high-risk individuals and surgical repair when the risk of rupture exceeds the risk of repair, typically at 5.5 cm in diameter5. However, most AAAs are asymptomatic, and many are diagnosed incidentally6. As such, efforts should be made to identify high-risk patients and develop non-surgical treatments to reduce AAA growth and, therefore, the risk of rupture.
To develop medical treatments for AAA, the pathogenesis must be better understood. Several experimental models are currently used, including small-animal models utilizing angiotensin II infusion7, xenografting8, calcium chloride application9, and infusion10 and/or topical application of elastase11. Each of these models uses a different understanding of the pathologic basis of AAA, and most have been modified, improved, or combined with other methods since inception.
Importantly, AAA histology demonstrates loss of the normal lamellar elastin matrix, which is also seen in lung tissue in chronic obstructive pulmonary disease12,13. Elastin degradation via matrix metalloproteinase activity provides an important linkage between AAA pathogenesis and smoking, the most important modifiable risk factor for AAA formation12,14. Notably, reduced aortic elastin, elastin fiber disruption, and increased circulating elastin peptides are observed in human AAA and are associated with increased AAA wall distensibility15,16. Therefore, stimulating elastin degradation is crucial in creating a translatable AAA model. Existing AAA models that rely on elastin degradation, while effective, can be complicated by high animal mortality rates, especially in models that use aortic cannulation17, and by inconsistent aneurysm formation, particularly in models that rely solely on topical elastase application18. Furthermore, all models relying on induction surgeries are subject to operator learning curves and technical variation.
To address these issues, we leverage the host immune response to sensitize animals to elastin by injecting elastin degradation products (EDP). One week later, aneurysm induction surgery occurs in a standardized stepwise fashion, using periaortic application of elastase to create EDP moieties for the sensitized host to mount an immune response against. Subsequent “booster” EDP sensitization, a week after induction surgery, ensures the host immune response continues. Repetitive immune sensitization enables reliable aortic dilation. We utilize a murine AAA model due to lower cost, ease of maintenance, rapid disease development, and technical consistency.
This model does not reliably result in aortic rupture and is therefore not intended for the study of factors associated with AAA rupture. However, this model does reliably produce progressive aortic dilation to 21 days post-induction surgery. As such, the model is best suited to studying therapeutic modalities that may reduce or reverse aortic dilation as the aneurysm is forming.